Take Homes in Lung Cancer

Take Homes in Lung Cancer

Source:

Healio Interview

Disclosures: Gandara reports receiving institutional research grants from Amgen, AstraZeneca, Genentech and Merck; and serving as a consultant or on advisory boards for AstraZeneca (institutional), Roche-Genentech (institutional), Guardant Health (institutional), Inivata, IO Biotech (institutional), Lilly, Merck, Novartis and Oncocyte (institutional)
August 17, 2021
1 min watch
Save

VIDEO: ILCC panel discusses osimertinib in practice, impact of ADAURA data

Source:

Healio Interview

Disclosures: Gandara reports receiving institutional research grants from Amgen, AstraZeneca, Genentech and Merck; and serving as a consultant or on advisory boards for AstraZeneca (institutional), Roche-Genentech (institutional), Guardant Health (institutional), Inivata, IO Biotech (institutional), Lilly, Merck, Novartis and Oncocyte (institutional)
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, David R. Gandara, MD, spoke with Healio about discussions surrounding the ADAURA trial held at the 22nd annual International Lung Cancer Congress.

“We use this opportunity at ILCC to both update the data and to have a panel discussion regarding how we’re using this information in practice,” Gandara, director of the thoracic oncology program at UC Davis Comprehensive Cancer Center and chief medical officer for the International Society of Liquid Biopsy, said.